Amgen Inc. moved to a key stage for its potential blockbuster drug denosumab on Monday when the Food and Drug Administration announced that a panel would review the drug, which is an experimental ...
LOS ANGELES, Aug 9 (Reuters) - Thursday's U.S. Food and Drug Administration advisory panel review of denosumab, Amgen Inc's experimental osteoporosis drug, will likely center on safety, particularly ...
LOS ANGELES, Aug 9 (Reuters) - Thursday's U.S. Food and Drug Administration advisory panel review of denosumab, Amgen Inc's experimental osteoporosis drug, will likely center on safety, particularly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results